Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $13.1 million.

  • Ligand Pharmaceuticals' Cash from Operations fell 6416.64% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year decrease of 5835.78%. This contributed to the annual value of $97.0 million for FY2024, which is 9575.0% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Cash from Operations stood at $13.1 million, which was down 6416.64% from $15.8 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Cash from Operations' 5-year high stood at $53.5 million during Q4 2022, with a 5-year trough of -$25.4 million in Q1 2025.
  • For the 5-year period, Ligand Pharmaceuticals' Cash from Operations averaged around $19.3 million, with its median value being $18.7 million (2024).
  • In the last 5 years, Ligand Pharmaceuticals' Cash from Operations soared by 1633658.54% in 2024 and then plummeted by 23583.71% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Cash from Operations stood at $27.6 million in 2021, then surged by 93.44% to $53.5 million in 2022, then crashed by 84.92% to $8.1 million in 2023, then skyrocketed by 253.02% to $28.5 million in 2024, then crashed by 54.02% to $13.1 million in 2025.
  • Its Cash from Operations stands at $13.1 million for Q3 2025, versus $15.8 million for Q2 2025 and -$25.4 million for Q1 2025.